Mesoblast Limited - American Depositary Shares - Nakit Akışı (NASDAQ:MESO)

Financials

İşletme faaliyetlerinden elde edilen nakit 106.68 M65.78 M63.27 M48.46 M49.95 M — Yatırım faaliyetlerinden elde edilen nakit 1.65 M232 K194 K97 K120 K — Finansman faaliyetlerinden elde edilen nakit 114.47 M9.87 M74.5 M40.25 M147.34 M — Serbest nakit akışı 106.68 M65.78 M63.27 M48.46 M49.95 M —

Mesoblast Limited - American Depositary Shares

Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.

MESO

Financials

Mesoblast Limited - American Depositary Shares

Haberler

Mesoblast bel ağrısı tedavisi denemesinde kayıtları tamamladı

Mesoblast, Mayo Clinic’ten CAR teknolojisi lisansı aldı

Mesoblast Limited: A Risk/Reward Story (NASDAQ:MESO)

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript

Mesoblast kazancı $0,02 ile beklentilere göre daha iyi, kâr ise beklentilere göre düşük

Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade) (NASDAQ:MESO)

Mesoblast H1 FY26 slides: first approved MSC product hits $49M

Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication - Mesoblast (NASDAQ:MESO)

FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain - Mesoblast (NASDAQ:MESO)

Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session - American Express (NYSE:AXP), Bread Finl Hldgs (NYSE:BFH)

Mesoblast hissesi 21,05 dolar ile 52 haftalık zirveye ulaştı

Mesoblast stock reaches 52-week high at 21.05 USD